Therasid Bioscience
Welcome,         Profile    Billing    Logout  
 33 Trials 
24 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Sang Il
NCT05701540: A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

Recruiting
4
338
RoW
Tegoprazan, Esomeprazole
HK inno.N Corporation
Gastroesophageal Reflux Disease
12/24
12/24
NCT05051332: Phase 3 Clinical Trial of CartiLife® in Korea

Active, not recruiting
3
104
RoW
Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery
Biosolution Co., Ltd.
Articular Cartilage Defect, Articular Cartilage Degeneration
09/23
09/24
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT06466785: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Recruiting
3
429
RoW
Efepoetin Alfa, GX-E4, Darbepoetin Alfa, Aranesp®
Genexine, Inc., PT Kalbe Genexine Biologics
Anemia of Chronic Kidney Disease
12/26
09/27
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting
3
408
RoW
Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine
GC Cell Corporation
Pancreatic Ductal Adenocarcinoma
12/26
06/27
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Chinook Therapeutics, Inc.
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
NCT05944627: Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis

Not yet recruiting
1/2
68
NA
FURESTEM-OA Kit Inj., Placebo
Kang Stem Biotech Co., Ltd.
Knee Osteoarthritis
03/24
02/26
NCT05045534: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

Completed
1
96
RoW
Comparison of TB-840 treatment with Placebo, TB-840
Therasid Bioscience
Healthy Volunteers
08/22
12/22
DENEX HTN-KORAS, NCT04307836: DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications

Recruiting
N/A
140
RoW
Renal Denervation
Kalos Medical
Hypertension, Vascular Diseases, Cardiovascular Diseases
07/23
04/24
NCT06120348: Study of Application of Pulse Electrical Stimulation Around Eye in Dry Eye Disease Patients Who Are Scheduled for Laser Epithelial Keratomileusis (LASEK) Surgery

Recruiting
N/A
178
RoW
Charge-Balanced, Symmetric Nerve Stimulation, Sham Stimulation
Nu Eyne Co., Ltd.
Dry Eye Disease
04/24
08/24
NCT06427083: Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Recruiting
N/A
240
RoW
Envlo Tablet, Envolomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
12/25
06/26
NCT06419816: Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus

Recruiting
N/A
480
RoW
Physician-managed "WellCheck" use, self-managed "WellCheck" use
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
12/25
06/26
NCT05493904: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)

Recruiting
N/A
320
RoW
OCT-guided PCI, Angiography-guided PCI, Drug-eluting stent
Chonnam National University Hospital, Abbott Medical Devices
Coronary Artery Disease, Angina Pectoris
08/24
12/26
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD

Recruiting
N/A
2400
RoW
Percutaneous Coronary Intervention
Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd
Coronary Disease
12/26
07/30
Symphony, NCT04912674: Evaluation of ™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity

Recruiting
N/A
100
US
Symphony OCT System
International Spine Study Group Foundation, DePuy Synthes
Cervical Deformity
07/27
07/27
NCT06013306: Long-Term Follow-up Study of Subjects With Knee Osteoarthritis Who Had Administered FURESTEM-OA Kit Inj. in K0701 Study

Not yet recruiting
N/A
58
NA
Kang Stem Biotech Co., Ltd.
Knee Osteoarthritis
11/29
12/30
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0

Recruiting
N/A
200
US
Surgical intervention
International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc.
Cervical Deformity
12/32
07/33
Shin, YoungHee
NCT05045534: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

Completed
1
96
RoW
Comparison of TB-840 treatment with Placebo, TB-840
Therasid Bioscience
Healthy Volunteers
08/22
12/22

Download Options